China
Africa
Explore chapters and articles related to this topic
Tissue Phenomics For Diagnostic Pathology
Published in Gerd Binnig, Ralf Huss, Günter Schmidt, Tissue Phenomics, 2018
Based on research by Galon et al. (2012) and applying tissue phenomics, HalioDx Inc. developed the Immunoscore®. The Immunoscore integrates IHC in combination with advanced imaging analysis solutions to enable the extraction of spatial information in colon cancer. This is a diagnostic tool for routine pathology and exploratory application in immuno-oncology, which offers image and data analysis for the identification and quantification of certain immune cells in predefined cancer regions (e.g., immune cell density in the invasive margin versus the tumor center). While the Immunoscore is currently designed for colon cancer, it has the potential to be a platform for many cancers to determine the immune landscape in individual tumors to better predict disease progression and response to therapy. The clinical evaluation is currently ongoing.
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
Published in OncoImmunology, 2023
Assia Hijazi, Carlotta Antoniotti, Chiara Cremolini, Jérôme Galon
In this study analysis (n = 216 patients), the Immunoscore-IC pass rate was 100%, disclosing therefore the feasibility of this test.44 Immunoscore-IC High represented a large proportion (32%) of MSS patients, who display strong and significant survival benefits when receiving combination-immunotherapy (HR = 0.35 [95% CI 0.16–0.73], P < 0.001). Kaplan Meier estimates of PFS in the pMMR subgroup (MSS patients) based on Immunoscore-IC revealed prolonged survival only in patients with Immunoscore-IC-High in the combination-immunotherapy arm. The median PFS of Immunoscore IC-low in the standard of care arm or in the combination-immunotherapy arm was up to 12 and 11 months, respectively. The median PFS of Immunoscore IC-high in the standard of care arm was also up to 9 months. In contrast, the median PFS of Immunoscore IC-high in the combination-immunotherapy arm was not reached and is superior to 25 months. A recent report at the ASCO meeting 2023 confirmed these results for overall survival (OS). This demonstrates the predictive value of Immunoscore-IC for response to combination-immunotherapy in first-line pMMR metastatic CRC.44
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Published in Expert Opinion on Biological Therapy, 2021
Colorectal cancers with microsatellite instability-high (MSI-H) are characterized by high tumor mutation burden (TMB), robust Th1-type immune infiltration and high expression of multiple immune checkpoints such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Microsatellite stable (MSS) colorectal cancers are associated with considerably lower TMB and less immune infiltration [8]. Interestingly, about 45% of MSS and 65% of MSI-H colorectal cancer had a high Immunoscore, while 55% of MSS and 35% of MSI-H colorectal cancer had a low Immunoscore, suggesting that some of the MSI-H tumors are unable to mount an antitumor response while the reverse may apply for some of the MSS population [9]. However, the Immunoscore assay has not been validated yet as a predictor biomarker for immunotherapy response.
Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer
Published in OncoImmunology, 2021
Elise F. Nassif, Constance Thibault, Stéphane Oudard, Jérôme Galon
The different subpopulations of immune cells are associated with variable prognostic significance.2,3 Multiple analyses and meta-analyses have highlighted the role of particular subpopulation of adaptive immune cells. In particular, T lymphocytes and cytotoxic T-cells have a major influence on patient survival.2–6 Recently, the international consortium of the Consensus Immunoscore validated the prediction of clinical outcome and response to chemotherapy.7–9 Multiple studies and analysis were performed to validate the analytical performance of Immunoscore.9,10 Immunoscore can provide new information on host-defense against the tumor, which is an essential element in the success of immunotherapy and of any cancer therapy mobilizing the immune response.11,12